User profiles for Wenming Xiao

Wenming Xiao

Office of Oncologic Diseases, CDER/FDA
Verified email at fda.hhs.gov
Cited by 16247

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

…, S Carty, LT Lam, AL Shaffer, W Xiao… - Proceedings of the …, 2008 - National Acad Sciences
Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B-cell
lymphoma (DLBCL), termed germinal center B-cell-like (GCB) DLBCL, activated B-cell-…

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

…, H Zhao, Y Yang, W Xu, AL Shaffer, G Wright, W Xiao… - Nature, 2010 - nature.com
A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by studying
immunoglobulin genes in human lymphomas 1 , 2 and by engineering mouse models 3 , …

[PDF][PDF] Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

…, NCT Emre, M Ceribelli, M Zhang, G Wright, W Xiao… - Cancer cell, 2012 - cell.com
Knowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically
lethal, affecting cancer cells while sparing normal cells. Lenalidomide is an active agent in …

[HTML][HTML] Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays

Y Wang, C Barbacioru, F Hyland, W Xiao… - BMC genomics, 2006 - Springer
Background DNA microarrays are rapidly becoming a fundamental tool in discovery-based
genomic and biomedical research. However, the reliability of the microarray results is being …

[HTML][HTML] Genetics and pathogenesis of diffuse large B-cell lymphoma

…, AL Shaffer, DJ Hodson, W Xiao… - New England journal …, 2018 - Mass Medical Soc
Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell…

Oncogenically active MYD88 mutations in human lymphoma

VN Ngo, RM Young, R Schmitz, S Jhavar, W Xiao… - Nature, 2011 - nature.com
The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains
the least curable form of this malignancy despite recent advances in therapy 1 . Constitutive …

[PDF][PDF] Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma

…, F Zhan, G Lenz, I Hanamura, G Wright, W Xiao… - Cancer cell, 2007 - cell.com
Mechanisms of constitutive NF-κB signaling in multiple myeloma are unknown. An inhibitor
of IκB kinase β (IKKβ) targeting the classical NF-κB pathway was lethal to many myeloma cell …

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

R Schmitz, RM Young, M Ceribelli, S Jhavar, W Xiao… - Nature, 2012 - nature.com
Burkitt’s lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of
such therapy precludes its use in the elderly and in patients with endemic BL in developing …

IRF4 addiction in multiple myeloma

…, NCT Emre, L Lamy, VN Ngo, G Wright, W Xiao… - Nature, 2008 - nature.com
The transcription factor IRF4 (interferon regulatory factor 4) is required during an immune
response for lymphocyte activation and the generation of immunoglobulin-secreting plasma …

[HTML][HTML] Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

…, B Jiang, X Hu, W Zhang, JKC Chan, W Xiao… - Nature …, 2015 - nature.com
Lymphomas arising from NK or γδ-T cells are very aggressive diseases and little is known
regarding their pathogenesis. Here we report frequent activating mutations of STAT3 and …